58 results on '"Ceribelli A."'
Search Results
2. Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network
3. Genomic binding of NF-Y in mouse and human cells
4. The autoimmune landscape of Porto-sinusoidal vascular disorder: What the rheumatologist needs to know
5. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
6. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas
7. Patient global assessment and inflammatory markers in patients with idiopathic inflammatory myopathies – A longitudinal study
8. Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics
9. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma
10. Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1
11. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
12. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
13. Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
14. Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma
15. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY
16. Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non–Small-cell Lung Cancer: A Multicenter Italian Survey
17. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
18. Isoform-Specific Expression and Feedback Regulation of E Protein TCF4 Control Dendritic Cell Lineage Specification
19. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm
20. Subjective qualitative assessment of the finish line of prosthetic preparations submitted to different finishing instruments
21. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
22. Best practices to optimize intraoperative photography
23. Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells
24. High-throughput approaches to uncover synergistic drug combinations in leukemia
25. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
26. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
27. EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
28. Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial
29. Chapter 53 - Clinical and Laboratory Evaluation of Systemic Autoimmune Rheumatic Diseases
30. KiRNet: Kinase-centered network propagation of pharmacological screen results
31. NF-YC Complexity Is Generated by Dual Promoters and Alternative Splicing
32. Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones
33. Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies
34. Molecular Mechanism of Action of Glucocorticoids in Lymphoma Therapy
35. Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement
36. Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
37. MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
38. POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
39. Gender Differences: Implications for Clinical Trials and Practice
40. The THAP–zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes
41. Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters
42. NF-Y Regulates the Antisense Promoter, Bidirectional Silencing, and Differential Epigenetic Marks of the Kcnq1 Imprinting Control Region
43. Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
44. Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression
45. Contributors
46. Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
47. Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas
48. Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
49. Chapter 10 - The Interplay of Epigenetics and Epidemiology in Autoimmune Diseases: Time for Geoepigenetics
50. Comment on: Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.